

How to access zanubrutinib - a patients guide

Following the decision from the National Institute for Clinical Excellence (NICE), we know patients are concerned about accessing zanubrutinib. We've put together this handy guide to help you access it (and what you need to ask your consultant).

Zanubrutinib is still only available as a **second line treatment**, and can only be offered if your consultant would *consider* treating you with Bendamustine and Rituximab) as a second line treatment.

If you've had a first line treatment (BR, DRC or other type) and you relapse, you will need to establish with your consultant whether you are *suitable* for BR as a second line treatment.

If your consultant *considers* you a suitable candidate for BR, you would be eligible for Zanubrutinib.

You do not actually need to receive BR treatment in order to qualify.

The consultant needs to complete the standard 'Blueteq' online prescribing form and tick the box saying that you **'would be suitable for BR'**.

This form is on a national website, available to all NHS doctors who prescribe NICE-approved medication. The form produces an instant approval and zanubrutinib can be prescribed and dispensed the same day.

Note: the vast majority of patients who have previously received BR therapy for their WM are likely to be suitable for Zanubrutinib. Always discuss any plans for future treatment with your clinician.